CLINICAL TRIALS PROFILE FOR ALIMTA

All Clinical Trials for ALIMTA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00022646 ↗	Pemetrexed Disodium Plus Gemcitabine in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Completed	National Cancer Institute (NCI)	Phase 2	2001-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug and giving the drugs in different ways may kill more tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of three different regimens of pemetrexed disodium plus gemcitabine in treating patients who have locally advanced or metastatic non-small cell lung cancer.
NCT00022646 ↗	Pemetrexed Disodium Plus Gemcitabine in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Completed	Alliance for Clinical Trials in Oncology	Phase 2	2001-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug and giving the drugs in different ways may kill more tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of three different regimens of pemetrexed disodium plus gemcitabine in treating patients who have locally advanced or metastatic non-small cell lung cancer.
NCT00034463 ↗	ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer	Completed	Eli Lilly and Company	Phase 1	1969-12-31	This is a non-randomized, phase 1, study with the primary objective of determining the toxicities and establishing the maximum tolerated dose of ALIMTA when administered as a 10 minute infusion every 21 days with folic acid or multi-vitamin supplementation therapy in lightly or heavily pre-treated patients with locally advanced or metastatic cancer.
NCT00034502 ↗	A Trial of ALIMTA (Pemetrexed) Plus Irinotecan in Patients Who Have Been Previously Treated For Metastatic Colorectal Cancer.	Completed	Eli Lilly and Company	Phase 1/Phase 2	1969-12-31	This is a non-randomized study in patients who have received prior 5-FU therapy for colorectal cancer. The objective of this trial is to establish a maximum tolerated dose of ALIMTA and irinotecan given in combination as well as to assess the safety and efficacy of this combination for patients with locally advanced or metastatic colorectal cancer. ALIMTA and irinotecan will be given every 21 days.
NCT00034593 ↗	A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium	Completed	Eli Lilly and Company	Phase 2	1969-12-31	Definition: Patients with bladder cancer will be participating in this study for the treatment of abnormal cells in the bladder that have returned after initial treatment OR have moved to a new site in the body.
NCT00034606 ↗	Comparing 3 Schedules of Alimta Plus Gemzar	Completed	Eli Lilly and Company	Phase 2	1969-12-31	The purpose of the study is to measure tumor response rates for three schedules of Alimta(LY231514) in combination with gemcitabine in patients with locally advanced or metastatic non small cell lung cancer who have received no prior chemotherapy regimen.
NCT00034619 ↗	A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer.	Completed	Eli Lilly and Company	Phase 2	1969-12-31	The purpose of this study is to assess the antitumor activity of ALIMTA plus Oxaliplatin combination therapy in patients with previously untreated advanced colorectal cancer

Clinical Trial Conditions for ALIMTA

Condition Name

Condition Name for ALIMTA
Intervention	Trials
Non-Small Cell Lung Cancer	53
Lung Cancer	34
Non Small Cell Lung Cancer	32
Carcinoma, Non-Small-Cell Lung	17

Condition MeSH

Condition MeSH for ALIMTA
Intervention	Trials
Carcinoma, Non-Small-Cell Lung	200
Lung Neoplasms	187
Mesothelioma	24
Carcinoma	21

Clinical Trial Locations for ALIMTA

Trials by Country

Trials by Country for ALIMTA
Location	Trials
China	88
United Kingdom	78
Spain	66
Italy	61
Canada	57

Trials by US State

Trials by US State for ALIMTA
Location	Trials
California	70
Pennsylvania	65
Florida	65
Texas	64
Ohio	62

Clinical Trial Progress for ALIMTA

Clinical Trial Phase

Clinical Trial Phase for ALIMTA
Clinical Trial Phase	Trials
Phase 4	6
Phase 3	52
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for ALIMTA
Clinical Trial Phase	Trials
Completed	196
Terminated	54
Recruiting	28

Clinical Trial Sponsors for ALIMTA

Sponsor Name

Sponsor Name for ALIMTA
Sponsor	Trials
Eli Lilly and Company	145
National Cancer Institute (NCI)	56
Merck Sharp & Dohme Corp.	14

Sponsor Type

Sponsor Type for ALIMTA
Sponsor	Trials
Industry	268
Other	244
NIH	56